Pfizer's abrocitinib smashes primary and secondary endpoints at Phase 3 in atopic dermatitis

Pfizer has lifted the curtain on new Phase 3 data for its Janus kinase 1 (JAK1) inhibitor abrocitinib, revealing that the therapy met all of its co-primary and secondary endpoints in the treatment of moderate to severe atopic dermatitis (AD) in patients aged 12 and older.

The trial examined the safety and efficacy of both 100mg or 200mg once-daily doses of the drug. After 12 weeks of treatment, it was found that a higher proportion of patients receiving abrocitinib achieved a score of 1 or 2 on the Investigator Global Assessment (IGA), representing clear or almost clear skin, compared to placebo, meeting the trial’s primary endpoint.

Additionally, it was also found that a higher proportion of abrocitinib patients achieved a 75% or greater change from baseline according to the Eczema Area and Severity Index (EASI) than those receiving placebo, meeting the trial’s secondary endpoint.

The drug also achieved its secondary endpoints of a four-point or greater reduction in itch severity according to the pruritus numerical rating scale, and magnitude of decrease as measured by the Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD).

"Moderate to severe atopic dermatitis is a chronic, inflammatory skin disease that can take both a physical and emotional toll on the millions of patients living with the condition worldwide," said Dr Michael Corbo, Chief Development Officer of Inflammation & Immunology at Pfizer. "These top-line findings are encouraging and provide evidence that abrocitinib, if approved, could be an effective new oral once-daily treatment option for patients."

Matt Fellows

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.